Use of TNFalpha Antibody for Treatment of Hidradenitis Suppurativa (HS)

A method for treating a subject having moderate to severe hidradenitis suppurativa (HS), the method comprising:

• at week 0 administering a first loading dose of 160 mg of an isolated human anti-TNFα antibody, or antigen binding portion thereof, to the subject, wherein the first loading dose is administered as four 40 mg doses in one day or two 40 mg doses per day over two consecutive days;
• at week 2 administering a second loading dose of 80 mg of the human anti-TNFα antibody, or antigen binding portion thereof, to the subject, wherein the second loading dose is administered as two 40 mg doses in one day;
• and
• starting at week 4 administering a treatment dose of 40 mg of the human anti-TNFα antibody, or antigen binding portion thereof, to the subject weekly,
• wherein the anti-TNFα antibody, or antigen binding portion thereof, comprises a variable light chain comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO:
• 3;
• a CDR2 domain comprising the amino acid sequence of SEQ ID NO:
• 5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:
• 7;
• and comprises a variable heavy chain comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO:
• 4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:
• 6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:
• 8.

A method for decreasing the number of inflammatory lesions (AN count) in a subject having moderate to severe hidradenitis suppurativa (HS), said method comprising systemically

• at week 0 administering a first loading dose of 160 mg of an isolated human anti-TNFα antibody, or antigen binding portion thereof, to the subject, wherein the first loading dose is administered as four 40 mg doses in one day or two 40 mg doses per day over two consecutive days;
• at week 2 administering a second loading dose of 80 mg of the human anti-TNFα antibody, or antigen binding portion thereof, to the subject, wherein the second loading dose is administered as two 40 mg doses in one day;
• and
• starting at week 4 administering a treatment dose of 40 mg of the human anti-TNFα antibody, or antigen binding portion thereof, to the subject weekly,
• wherein the anti-TNFα antibody, or antigen binding portion thereof, comprises a variable light chain comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO:
• 3;
• a CDR2 domain comprising the amino acid sequence of SEQ ID NO:
• 5, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:
• 7;
• and comprises a variable heavy chain comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO:
• 4, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:
• 6, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:
• 8.

A method for treating a subject having moderate to severe hidradenitis suppurativa (HS), the method comprising:

• at week 0 subcutaneously administering a first loading dose of 160 mg of adalimumab to the subject, wherein the first loading dose of adalimumab is administered as four 40 mg doses in one day or two 40 mg doses per day over two consecutive days;
• at week 2 subcutaneously administering a second loading dose of 80 mg of adalimumab to the subject, wherein the second loading dose of adalimumab is administered as two 40 mg doses in one day;
• and
• starting at week 4 subcutaneously administering a maintenance dose of 40 mg of adalimumab to the subject weekly.